TW201920269A - IL-1β 結合抗體之用途 - Google Patents

IL-1β 結合抗體之用途 Download PDF

Info

Publication number
TW201920269A
TW201920269A TW107132268A TW107132268A TW201920269A TW 201920269 A TW201920269 A TW 201920269A TW 107132268 A TW107132268 A TW 107132268A TW 107132268 A TW107132268 A TW 107132268A TW 201920269 A TW201920269 A TW 201920269A
Authority
TW
Taiwan
Prior art keywords
individual
administration
kananazumab
days
administered
Prior art date
Application number
TW107132268A
Other languages
English (en)
Chinese (zh)
Inventor
薛發德 梅普福
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW201920269A publication Critical patent/TW201920269A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
TW107132268A 2017-09-13 2018-09-13 IL-1β 結合抗體之用途 TW201920269A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762557929P 2017-09-13 2017-09-13
US62/557,929 2017-09-13
US201862647088P 2018-03-23 2018-03-23
US62/647,088 2018-03-23

Publications (1)

Publication Number Publication Date
TW201920269A true TW201920269A (zh) 2019-06-01

Family

ID=63708416

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107132268A TW201920269A (zh) 2017-09-13 2018-09-13 IL-1β 結合抗體之用途

Country Status (14)

Country Link
US (3) US20200207848A1 (enExample)
EP (1) EP3717006A1 (enExample)
JP (1) JP2020533353A (enExample)
KR (1) KR20200052331A (enExample)
CN (1) CN111315412A (enExample)
AU (1) AU2018333106A1 (enExample)
BR (1) BR112020004903A2 (enExample)
CA (1) CA3075711A1 (enExample)
CL (1) CL2020000631A1 (enExample)
IL (1) IL273204A (enExample)
MX (1) MX2020002813A (enExample)
RU (1) RU2020113234A (enExample)
TW (1) TW201920269A (enExample)
WO (1) WO2019053591A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026145640A1 (zh) * 2025-01-03 2026-07-09 长春金赛药业有限责任公司 一种抗IL-1β抗体的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
WO2015083120A1 (en) * 2013-12-04 2015-06-11 Novartis Ag USE OF IL-1β BINDING ANTIBODIES
MX2016014731A (es) * 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
KR101695848B1 (ko) * 2015-03-03 2017-01-13 한국과학기술원 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2019053591A1 (en) 2019-03-21
JP2020533353A (ja) 2020-11-19
MX2020002813A (es) 2020-07-21
AU2018333106A1 (en) 2020-04-02
US20200207848A1 (en) 2020-07-02
CA3075711A1 (en) 2019-03-21
EP3717006A1 (en) 2020-10-07
IL273204A (en) 2020-04-30
US20230235043A1 (en) 2023-07-27
US20210309736A1 (en) 2021-10-07
RU2020113234A3 (enExample) 2022-04-28
CN111315412A (zh) 2020-06-19
CL2020000631A1 (es) 2020-09-11
RU2020113234A (ru) 2021-10-13
KR20200052331A (ko) 2020-05-14
BR112020004903A2 (pt) 2020-09-15

Similar Documents

Publication Publication Date Title
CA3018132C (en) Use of elafibranor in the treatment of a cholestatic disease
EP4142770B1 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
US11331292B2 (en) Methods of treatment of cholestatic diseases
US12290498B2 (en) Methods of treatment of cholestatic diseases
US20220378802A1 (en) Treatment of alcoholic hepatitis
KR20210027169A (ko) 비알콜성 지방간염(NASH, Nonalcoholic Steatohepatitis) 치료 또는 예방을 위한 약학 조성물
US20230235043A1 (en) Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
EP4346809A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
TW202144409A (zh) 抗vegf抗體和抗pd-1抗體組合用於預防或治療疾病的應用
TW202408522A (zh) 一種稠環嘧啶類化合物的用途
WO2026047132A1 (en) Treatment of advanced primary biliary cholangitis
CN110099686B (zh) 非酒精性脂肪性肝病的治疗
WO2025215081A1 (en) Elafibranor for use for long-term treatment of primary biliary cholangitis
JP2020533353A5 (enExample)
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
HK40012462B (en) Treatment of nonalcoholic fatty liver disease